The Roles of m6 A Modification in the Resistance of Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma
10.13865/j.cnki.cjbmb.2024.08.1211
- VernacularTitle:m6A甲基化修饰及功能相关蛋白质在肝癌免疫和靶向治疗耐药中的作用
- Author:
Le-Jie ZHANG
1
;
Qiong QIN
Author Information
1. 首都医科大学,北京100069
- Keywords:
N6-adenosine methylation (m6A);
hepatocellular carcinoma (HCC);
immunotherapy;
targeted therapy;
drug resistance
- From:
Chinese Journal of Biochemistry and Molecular Biology
2024;40(11):1513-1521
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the most prevalent and deadly malignancies world-wide,with many patients failing to benefit sustainably from emerging immunotherapies and targeted thera-pies due to drug resistance.Current commonly used biomarkers,such as alpha-fetoprotein (AFP ),tumor mutation burden (TMB),and programmed cell death protein 1 (PD-1),lack efficacy in indica-ting the outcomes of HCC immunotherapy and targeted therapy.Therefore,identifying effective biomark-ers to accurately predict therapeutic efficacy is crucial for optimizing clinical decision-making.Recent studies have shown that N6-methyladenosine (m6 A) modification,one of the most common and important RNA modifications in eukaryotes,plays a significant role in the HCC resistance to immunotherapy and targeted therapy.We summarize the research progress regarding to the roles and mechanisms of m6 A modification and its functional proteins in the resistance to immunotherapy and targeted therapy in HCC,and also discuss the potential application of m6 A modification as biomarkers for predicting the efficacy of these treatments.
